UK-based pharmaceutical company ViiV Healthcare has partnered with the Paediatric European Network for Treatment of AIDS (PENTA) Foundation to provide funding for PENTA’s Early-treated Perinatally HIV-infected Individuals: Improving Children’s Actual Life with Novel Immunotherapeutic Strategies (EPIICAL) consortium.

ViiV Healthcare is majority-owned by UK-based GlaxoSmithKline (GSK), with American company Pfizer and Japanese pharmaceutical company Shionogi as shareholders.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

ViiV Healthcare intends to fund for the consortium with an aim to develop optimal treatment strategies for children living with HIV, as well as to explore the potential for achieving disease remission.

The pharmaceutical company will also work in partnership with the PENTA Foundation and other leading paediatric HIV researchers worldwide, in a bid to evaluate the viral reservoir and immune characteristics of paediatric patients with HIV from previously established cohorts.

"Our collaboration with PENTA has set ambitious goals, but the need to optimise treatment strategies for children living with HIV is urgent."

The major concern behind the research is to develop models that can predict response to anti-retroviral treatment in order to maximise treatment for children affected with HIV.

See Also:

The PENTA EPIICAL consortium intends to use the result of this research in the design of new clinical studies of current and new therapies with the purpose to replicate the virologic and immunologic profile predicted by the model.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

ViiV Healthcare chief scientific and medical officer Dr John C Pottage said: "Our collaboration with PENTA has set ambitious goals, but the need to optimise treatment strategies for children living with HIV is urgent.

"The knowledge gained through this research will generate a deeper understanding of viral remission, which can be applied to the design of future clinical trials that test whether we can achieve what the model predicts in terms of HIV remission."

The information obtained, as well as the patient profiles, might also help inform the design of prospective studies with new and existing treatments meant for HIV remission and cure.